Aureus Asset Management LLC Acquires 2,298 Shares of Haleon plc (NYSE:HLN)

Aureus Asset Management LLC boosted its stake in shares of Haleon plc (NYSE:HLN) by 18.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 14,881 shares of the company’s stock after buying an additional 2,298 shares during the period. Aureus Asset Management LLC’s holdings in Haleon were worth $157,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. raised its holdings in shares of Haleon by 23.2% during the first quarter. B. Riley Wealth Advisors Inc. now owns 29,324 shares of the company’s stock worth $246,000 after acquiring an additional 5,519 shares during the period. Atria Investments Inc raised its stake in shares of Haleon by 5.7% in the 1st quarter. Atria Investments Inc now owns 181,557 shares of the company’s stock valued at $1,541,000 after purchasing an additional 9,746 shares during the period. Cetera Investment Advisers lifted its holdings in shares of Haleon by 106.3% in the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock valued at $1,985,000 after purchasing an additional 120,447 shares in the last quarter. Cetera Advisors LLC boosted its position in shares of Haleon by 524.3% during the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock worth $696,000 after buying an additional 68,857 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Haleon by 13.8% during the first quarter. EverSource Wealth Advisors LLC now owns 16,204 shares of the company’s stock worth $138,000 after buying an additional 1,962 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of NYSE HLN opened at $9.67 on Tuesday. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The stock has a 50 day moving average of $9.92 and a 200-day moving average of $9.44. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $43.77 billion, a P/E ratio of 28.44, a P/E/G ratio of 2.92 and a beta of 0.30.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Berenberg Bank started coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating on the stock. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Finally, Morgan Stanley increased their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.